Core Insights - ReShape Lifesciences is hosting its inaugural Lap-Band® Surgeon Summit from August 1-3, 2025, in Nashville, Tennessee, directed by Dr. Christine Ren-Fielding, a leading expert in bariatric surgery [1][2] - The Summit aims to enhance collaboration with top Lap-Band® surgeons to improve patient outcomes and expand access to the Lap-Band® system, including the new Lap-Band® 2.0 FLEX [2][3] Company Overview - ReShape Lifesciences is a premier company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band® System, which provides a minimally invasive treatment for obesity [4] - The company also has investigational products like the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system for type 2 diabetes and the Obalon® balloon technology for non-surgical weight loss [4] Product Focus - The Summit will discuss the benefits of the original Lap-Band® and the next-generation Lap-Band® 2.0 FLEX, emphasizing the integration of GLP-1 medications in patient care and strategies for patient education [2][3] - Early feedback from the limited U.S. market release of the Lap-Band® 2.0 FLEX has been overwhelmingly positive, indicating strong market interest and potential for growth [2]

Core Viewpoint - ReShape Lifesciences' Board of Directors unanimously recommends a merger with Vyome Therapeutics and an asset sale to Biorad Medisys, believing these actions are in the best interests of the company and its shareholders [2][3]. Group 1: Merger and Asset Sale Details - The merger with Vyome Therapeutics aims to enhance the development of immune-inflammatory assets and leverage opportunities between the US and India [3]. - The asset sale involves transferring substantially all of ReShape's assets to Biorad Medisys, which is expected to facilitate the company's transformation [2][3]. - Independent proxy advisory firms ISS and Glass Lewis have recommended shareholders vote in favor of the merger and asset sale proposals [2]. Group 2: Shareholder Engagement - The company emphasizes the importance of shareholder votes, urging all shareholders to vote in favor of the proposals related to the issuance of common stock, asset sale, and board composition amendments [3][4]. - Shareholders who have not yet voted are encouraged to do so, and those who voted against the proposals are asked to reconsider [4][6]. Group 3: Company Backgrounds - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band® System and the investigational Diabetes Bloc-Stim Neuromodulation™ system [11]. - Vyome Therapeutics focuses on developing therapies for immune-inflammatory conditions and plans to leverage its clinical-stage assets for growth [9]. - Biorad Medisys is a med-tech company with a focus on precision-engineered medical devices and has recently expanded its operations internationally [10].

Core Points - ReShape Lifesciences Inc. has regained compliance with Nasdaq's stockholders equity requirement, closing the listing matter [1][2] - The company previously faced potential delisting due to non-compliance with the minimum stockholders' equity requirement of $2.5 million [2] - As of March 31, 2025, the company's stockholders' equity was reported at $1.2 million [3] - The company raised a total of approximately $6.3 million through the sale of common stock in June 2025, which helped it regain compliance [3] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4] - The company provides the FDA-approved Lap-Band® System, which is a minimally invasive treatment for obesity [4] - Other offerings include an investigational vagal neuromodulation system for type 2 diabetes and metabolic disorders, and the non-surgical Obalon® balloon technology for weight loss [4]

Core Viewpoint - ReShape Lifesciences has announced a public offering of 1,054,604 shares of common stock at a price of $2.50 per share, expecting gross proceeds of approximately $2.6 million before expenses [1]. Group 1: Offering Details - The public offering is being conducted under an effective shelf registration statement filed with the SEC, which was declared effective on May 14, 2025 [3]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. - The offering is expected to close on or about June 9, 2025, pending customary closing conditions [1]. Group 2: Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4]. - The company’s FDA-approved products include the Lap-Band® systems, which provide minimally invasive treatment options for obesity, and the ReShape Diabetes Neuromodulation system, which targets glucose regulation [4]. - The Obalon® balloon technology is another innovative product that offers a non-surgical method for weight loss [4].